Published: 18 March 2021
Author(s): Rafael Dal-Ré, Rita Banzi
Issue: May 2021
Section: Commentary

Amid an unprecedented surge of COVID-19 cases in the UK, with an increasing number due to a novel more infectious SARS-CoV-2 variant,[1] the UK regulatory agency (MHRA) granted emergency approval to the AstraZeneca COVID-19 vaccine on 30 December 2020. The target population includes adults and elderly. The posology consisting of two separate doses given 4-12 weeks apart. Almost simultaneously, the UK health authorities recommended a dose interval of 12 weeks for both COVID-19 authorized vaccines (Pfizer/BioNTech; AstraZeneca), due to the shortage of doses and to vaccinate the highest number of citizens.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.